NYMX - Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate

Nymox Pharmaceutical (NYMX +7.8%) submitted a new drug application (NDA) to the FDA for Fexapotide Triflutate to treat men with benign prostatic hyperplasia (BPH). BPH also called prostate gland enlargement can cause uncomfortable urinary symptoms and can also cause bladder, urinary tract or kidney problems. The company said it intends to submit applications in other major markets in the near term. In the past year, the company had struggled with the filing of the NDA and had faced several delays.

For further details see:

Nymox stock rises 8% as it files for FDA approval of drug treating enlarged prostate